FDA Approves First Generic HIV Prevention Shot As Hopes Rise For Wider Global Access
The FDA tentatively approved Dr. Reddy’s Laboratories to produce a generic version of the HIV-prevention drug lenacapavir, a step toward expanding access in dozens of low- and middle-income countries; the reported annual cost is $40 per person. Other items in the briefing cover DEA registrations for more than 900 medical marijuana dispensaries, House Democrats seeking answers about U.S. citizens detained by immigration agents, and military-related developments involving Navy working conditions and deployments, veterans’ disability ratings, and restrictions affecting transgender Marines.
Stile giornalisticoFattuale
Primarily factual roundup of health policy reporting, with little subjective language.